8-K: Supernus Pharmaceuticals Receives FDA Approval for ONAPGO for Parkinson's Disease

Supernus Pharmaceuticals' ONAPGO (apomorphine hydrochloride) receives FDA approval as the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease.

Summary

• Supernus Pharmaceuticals has received FDA approval for ONAPGO (apomorphine hydrochloride) injection for the treatment of motor fluctuations (OFF episodes) in adults with advanced Parkinson's disease.
• ONAPGO is the first and only subcutaneous apomorphine infusion device for this indication.
• The drug will be available in the U.S. in the second quarter of 2025, supported by a nurse education program and access support.
• The approval is based on a Phase 3 study where ONAPGO significantly reduced daily OFF time by 2.6 hours compared to a 0.9-hour reduction in the placebo group (p=0.0114).
• The study also showed a significant increase in daily GOOD ON time of 2.8 hours for ONAPGO-treated patients versus 1.1 hours for the placebo group (p=0.0188).
• ONAPGO-treated patients reported improvement in their general health more frequently than placebo-treated patients (79% vs. 24%; p<0.0001).

Sentiment

Score: 8

Explanation: The document is positive due to the FDA approval of a new treatment for Parkinson's disease, which addresses an unmet need. The clinical trial results are promising, and the company has plans for a supportive launch. However, potential risks and side effects temper the overall sentiment.

Positives

• FDA approval of ONAPGO provides a new treatment option for Parkinson's disease patients experiencing motor fluctuations.
• ONAPGO offers a non-surgical, continuous infusion method for delivering apomorphine.
• Clinical trial results demonstrate a statistically significant reduction in OFF time and increase in GOOD ON time.
• The availability of a nurse education program and access support will aid in the successful adoption of ONAPGO.
• ONAPGO bypasses the GI tract, potentially leading to more predictable symptom improvement.

Negatives

• The most common adverse events (≥10% incidence) were infusion-site nodule, nausea, somnolence, infusion-site erythema, dyskinesia, headache, and insomnia.
• ONAPGO carries warnings and precautions, including the risk of blood clots, sleepiness, dizziness, falls, hallucinations, and heart problems.

Risks

• The company's ability to successfully commercialize ONAPGO is subject to market acceptance and competition.
• The company's future financial performance depends on its ability to increase prescriptions and net revenue.
• Clinical trials may not always predict real-world outcomes, and the long-term efficacy and safety of ONAPGO need to be monitored.
• The company faces risks related to intellectual property protection and potential infringement claims.

Future Outlook

Supernus plans to make ONAPGO available in the U.S. in the second quarter of 2025, supported by a nurse education program and access support.

Management Comments

• Jack Khattar, President and CEO of Supernus Pharmaceuticals, stated that the addition of ONAPGO demonstrates their continued commitment to developing novel alternatives to manage Parkinson's disease and other neurological conditions.
• Stuart Isaacson, M.D., Director of Parkinson's Disease and Movement Disorders Center of Boca Raton, Florida, noted that the subcutaneous delivery of apomorphine bypasses the GI tract and enters the brain, which can allow for more predictable symptom improvement.

Industry Context

The approval of ONAPGO provides a new option in a market with existing treatments like oral levodopa and other adjunct medications. It addresses the need for more consistent control of motor fluctuations in advanced Parkinson's disease, a common challenge as the disease progresses. The established use of subcutaneous apomorphine infusion in Europe for 30 years suggests a potential for successful adoption in the U.S.

Comparison to Industry Standards

• ONAPGO's continuous subcutaneous infusion delivery method is comparable to Duopa (carbidopa and levodopa) enteral suspension by AbbVie, which requires a surgical procedure for administration.
• Unlike oral medications like Sinemet (carbidopa/levodopa) or dopamine agonists such as Mirapex (pramipexole) and Requip (ropinirole), ONAPGO bypasses the gastrointestinal tract, potentially offering more consistent drug delivery.
• The 2.6-hour reduction in OFF time observed in the ONAPGO trial can be compared to the efficacy data of other treatments for motor fluctuations, such as inhaled levodopa (Inbrija by Acorda Therapeutics) or extended-release formulations of levodopa.

Stakeholder Impact

• Parkinson's disease patients and their families will benefit from a new treatment option for managing motor fluctuations.
• Healthcare providers will have a new tool to address the challenges of advanced Parkinson's disease.
• Supernus Pharmaceuticals' shareholders may see a positive impact on the company's financial performance.

Next Steps

• Supernus will make ONAPGO available in the U.S. in the second quarter of 2025.
• The company will implement a nurse education program and access support for ONAPGO.

Key Dates